aldosterone has been researched along with Recrudescence in 20 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aldosterone has also been shown to exert a number of effects in the central nervous system." | 6.44 | Aldosterone and the vasculature: mechanisms mediating resistant hypertension. ( Duprez, DA, 2007) |
| "Aldosterone appears to be a main marker of adverse clinical outcome, in accordance with the literature." | 5.40 | Prognostic role of aldosterone in patients with acute coronary syndrome: short and medium term follow-up. ( Arnone, G; Arnone, MT; Assennato, P; Corrado, E; Mignano, A; Novo, G; Novo, S; Pitruzzella, V; Rotolo, A, 2014) |
| "Five patients (three in the placebo and two in the spironolactone group) abandoned the treatment prior to ascites recurrence or the end of the study due to complications or lack of compliance." | 5.08 | Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo. ( Adler, M; Arroyo, V; Elewaut, A; Fernández-Esparrach, G; Geuvel, A; Ginès, P; Guevara, M; Jiménez, W; Lebrec, D; Pardo, A; Planas, R; Sort, P, 1997) |
| " Although the exact incidence of resistant hypertension is not established, estimates derived from recent outcome studies including the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Valsartan Antihypertensive Long-term Use Evaluation (VALUE), and Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) emphasize that this condition may be more common than previously thought." | 2.44 | Resistant hypertension: prevalence and evolving concepts. ( Epstein, M, 2007) |
| "Aldosterone has also been shown to exert a number of effects in the central nervous system." | 2.44 | Aldosterone and the vasculature: mechanisms mediating resistant hypertension. ( Duprez, DA, 2007) |
| "53% of the subjects experienced recurrence of AF." | 1.72 | Post-cardioversion time Course of Atrial Remodeling Markers and their Association with Recurrence in Subjects with Long-standing, Persistent Atrial Fibrillation. ( Blanco-Favela, F; Chávez-Sánchez, L; González-Hermosillo, A; Madrid-Miller, A; Martinez-Flores, E; Moreno-Ruiz, LA; Vazquez-González, W; Wacher-Rodarte, N; Zamorano-Velázquez, N, 2022) |
| "Aldosterone appears to be a main marker of adverse clinical outcome, in accordance with the literature." | 1.40 | Prognostic role of aldosterone in patients with acute coronary syndrome: short and medium term follow-up. ( Arnone, G; Arnone, MT; Assennato, P; Corrado, E; Mignano, A; Novo, G; Novo, S; Pitruzzella, V; Rotolo, A, 2014) |
| "Primary aldosteronism (PA) is the most common endocrine form of hypertension and may carry an increased risk of atrial flutter or fibrillation (AFF)." | 1.39 | Prospective appraisal of the prevalence of primary aldosteronism in hypertensive patients presenting with atrial flutter or fibrillation (PAPPHY Study): rationale and study design. ( Belfiore, A; Bernini, G; Caielli, P; Cipollone, F; Cottone, S; Ferri, C; Gallina, V; Giacchetti, G; Grassi, G; Leoni, L; Letizia, C; Maccario, M; Mantero, F; Morganti, A; Muiesan, ML; Olivieri, O; Palumbo, G; Pengo, M; Pessina, AC; Ragazzo, F; Rizzoni, D; Rossi, E; Rossi, GP; Seccia, TM; Sechi, L; Volpe, M, 2013) |
| "However, new-onset or worsening hepatic encephalopathy was seen in 14 patients." | 1.30 | Treatment of refractory ascites using transjugular intrahepatic portosystemic shunt (TIPS): a caution. ( Dufresne, MP; Fenyves, D; Lafortune, M; Legault, L; Martinet, JP; Pomier-Layrargues, G; Roy, L; Spahr, L, 1997) |
| "Aldosterone treatment was associated with a decrease in renin activity and a non-significant increase in mean arterial pressure." | 1.29 | Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist. ( Bauters, C; Bertrand, ME; Dupuis, B; Hamon, M; Lablanche, JM; McFadden, EP; Racadot, A; Van Belle, E; Wernert, N, 1995) |
| "Two adults with Bartter's syndrome were treated first with propranolol and a potassium-sparing diuretic and then with indomethacin for 22 months." | 1.26 | [Bartter's syndrome: Recurrence in the course of a treatment inhibiting prostaglandin synthesis]. ( Dray, F; Favre, L; Flory, ED; Glasson, P; Vallotton, MB, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (25.00) | 18.7374 |
| 1990's | 6 (30.00) | 18.2507 |
| 2000's | 2 (10.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moreno-Ruiz, LA | 1 |
| Chávez-Sánchez, L | 1 |
| Vazquez-González, W | 1 |
| Madrid-Miller, A | 1 |
| Zamorano-Velázquez, N | 1 |
| Martinez-Flores, E | 1 |
| Wacher-Rodarte, N | 1 |
| González-Hermosillo, A | 1 |
| Blanco-Favela, F | 1 |
| Mignano, A | 1 |
| Pitruzzella, V | 1 |
| Arnone, G | 1 |
| Arnone, MT | 1 |
| Rotolo, A | 1 |
| Assennato, P | 1 |
| Novo, G | 1 |
| Corrado, E | 1 |
| Novo, S | 1 |
| Scholl, UI | 1 |
| Stölting, G | 1 |
| Nelson-Williams, C | 1 |
| Vichot, AA | 1 |
| Choi, M | 1 |
| Loring, E | 1 |
| Prasad, ML | 1 |
| Goh, G | 1 |
| Carling, T | 1 |
| Juhlin, CC | 1 |
| Quack, I | 1 |
| Rump, LC | 1 |
| Thiel, A | 1 |
| Lande, M | 1 |
| Frazier, BG | 1 |
| Rasoulpour, M | 1 |
| Bowlin, DL | 1 |
| Sethna, CB | 1 |
| Trachtman, H | 1 |
| Fahlke, C | 1 |
| Lifton, RP | 1 |
| Lewicka, E | 1 |
| Dudzińska-Gehrmann, J | 1 |
| Dąbrowska-Kugacka, A | 1 |
| Zagożdżon, P | 1 |
| Stepnowska, E | 1 |
| Liżewska, A | 1 |
| Kozłowski, D | 1 |
| Raczak, G | 1 |
| Gurgoze, MK | 1 |
| Gunduz, Z | 1 |
| Poyrazoglu, MH | 1 |
| Dursun, I | 1 |
| Uzum, K | 1 |
| Dusunsel, R | 1 |
| Rossi, GP | 1 |
| Seccia, TM | 1 |
| Gallina, V | 1 |
| Muiesan, ML | 1 |
| Leoni, L | 1 |
| Pengo, M | 1 |
| Ragazzo, F | 1 |
| Caielli, P | 1 |
| Belfiore, A | 1 |
| Bernini, G | 1 |
| Cipollone, F | 1 |
| Cottone, S | 1 |
| Ferri, C | 1 |
| Giacchetti, G | 1 |
| Grassi, G | 1 |
| Letizia, C | 1 |
| Maccario, M | 1 |
| Olivieri, O | 1 |
| Palumbo, G | 1 |
| Rizzoni, D | 1 |
| Rossi, E | 1 |
| Sechi, L | 1 |
| Volpe, M | 1 |
| Mantero, F | 1 |
| Morganti, A | 1 |
| Pessina, AC | 1 |
| Andersen, RF | 1 |
| Nørgaard, H | 1 |
| Hagstrøm, S | 1 |
| Bjerre, J | 1 |
| Jespersen, B | 1 |
| Rittig, S | 1 |
| CHRISTIAENS, L | 1 |
| FONTAINE, G | 1 |
| LEFEBVRE, R | 1 |
| FOSSATI, P | 1 |
| Epstein, M | 1 |
| Duprez, DA | 1 |
| Van Belle, E | 1 |
| Bauters, C | 1 |
| Wernert, N | 1 |
| Hamon, M | 1 |
| McFadden, EP | 1 |
| Racadot, A | 1 |
| Dupuis, B | 1 |
| Lablanche, JM | 1 |
| Bertrand, ME | 1 |
| Hanukoglu, A | 1 |
| Bistritzer, T | 1 |
| Rakover, Y | 1 |
| Mandelberg, A | 1 |
| Martinet, JP | 1 |
| Fenyves, D | 1 |
| Legault, L | 1 |
| Roy, L | 1 |
| Dufresne, MP | 1 |
| Spahr, L | 1 |
| Lafortune, M | 1 |
| Pomier-Layrargues, G | 1 |
| Fernández-Esparrach, G | 1 |
| Guevara, M | 1 |
| Sort, P | 1 |
| Pardo, A | 1 |
| Jiménez, W | 1 |
| Ginès, P | 1 |
| Planas, R | 1 |
| Lebrec, D | 1 |
| Geuvel, A | 1 |
| Elewaut, A | 1 |
| Adler, M | 1 |
| Arroyo, V | 1 |
| Di Carlo, C | 1 |
| Bruno, P | 1 |
| Cirillo, D | 1 |
| Morgera, R | 1 |
| Pellicano, M | 1 |
| Nappi, C | 1 |
| Favre, L | 1 |
| Glasson, P | 1 |
| Flory, ED | 1 |
| Dray, F | 1 |
| Vallotton, MB | 1 |
| Picco, P | 1 |
| Garibaldi, L | 1 |
| Cotellessa, M | 1 |
| DiRocco, M | 1 |
| Borrone, C | 1 |
| Siegal, AM | 1 |
| Kreisberg, RA | 1 |
| Hershman, JM | 1 |
| Owen, WC | 1 |
| Brown, JJ | 1 |
| Chinn, RH | 1 |
| Fraser, R | 1 |
| Lever, AF | 1 |
| Morton, JJ | 1 |
| Robertson, JI | 1 |
| Tree, M | 1 |
| Waite, MA | 1 |
| Park, DM | 1 |
| Aperia, A | 1 |
| Berg, U | 1 |
| Broberger, O | 1 |
2 reviews available for aldosterone and Recrudescence
| Article | Year |
|---|---|
Resistant hypertension: prevalence and evolving concepts.
Topics: Aldosterone; Humans; Hypertension; Prevalence; Recurrence; Sleep Apnea, Obstructive; Treatment Failu | 2007 |
Aldosterone and the vasculature: mechanisms mediating resistant hypertension.
Topics: Aldosterone; Angiotensin II; Autonomic Nervous System; Endothelium; Humans; Hypertension; Muscle, Sm | 2007 |
1 trial available for aldosterone and Recrudescence
| Article | Year |
|---|---|
Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo.
Topics: Aldosterone; Ascites; Combined Modality Therapy; Diuretics; Dose-Response Relationship, Drug; Double | 1997 |
17 other studies available for aldosterone and Recrudescence
| Article | Year |
|---|---|
Post-cardioversion time Course of Atrial Remodeling Markers and their Association with Recurrence in Subjects with Long-standing, Persistent Atrial Fibrillation.
Topics: Aldosterone; Angiotensin II; Atrial Fibrillation; Atrial Remodeling; Biomarkers; Electric Countersho | 2022 |
Prognostic role of aldosterone in patients with acute coronary syndrome: short and medium term follow-up.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aldosterone; Arrhythmias, Cardiac; Biomarkers; Chi | 2014 |
Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism.
Topics: Adolescent; Adult; Age of Onset; Aldosterone; Amino Acid Sequence; Calcium; Calcium Channels, T-Type | 2015 |
Plasma biomarkers as predictors of recurrence of atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aldosterone; Atrial Fibrillation; Atrial Natriuretic Factor; Electric Count | 2015 |
Role of sodium during formation of edema in children with nephrotic syndrome.
Topics: Albumins; Aldosterone; Atrial Natriuretic Factor; Blood Volume; Body Water; Child; Child, Preschool; | 2011 |
Prospective appraisal of the prevalence of primary aldosteronism in hypertensive patients presenting with atrial flutter or fibrillation (PAPPHY Study): rationale and study design.
Topics: Aldosterone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Biomarkers; Chi-Square Dis | 2013 |
High plasma aldosterone is associated with a risk of reversible decreased eGFR in childhood idiopathic nephrotic syndrome.
Topics: Adolescent; Albuminuria; Aldosterone; Blood Volume; Child; Child, Preschool; Echocardiography; Femal | 2013 |
[Recurring paralysis with hyperaldosteronism].
Topics: Aldosterone; Humans; Hyperaldosteronism; Paralysis; Recurrence | 1960 |
Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist.
Topics: Aldosterone; Angioplasty, Balloon; Animals; Aorta; Blood Pressure; Coronary Disease; Iliac Artery; R | 1995 |
Pseudohypoaldosteronism with increased sweat and saliva electrolyte values and frequent lower respiratory tract infections mimicking cystic fibrosis.
Topics: Aldosterone; Child; Cystic Fibrosis; Diagnosis, Differential; Diseases in Twins; Female; Humans; Inf | 1994 |
Treatment of refractory ascites using transjugular intrahepatic portosystemic shunt (TIPS): a caution.
Topics: Aged; Aldosterone; Ascites; Creatinine; Diuretics; Female; Hepatic Encephalopathy; Humans; Hypertens | 1997 |
Increased concentrations of renin, aldosterone and Ca125 in a case of spontaneous, recurrent, familial, severe ovarian hyperstimulation syndrome.
Topics: Adult; Aldosterone; Calcium; Estradiol; Female; Fluid Therapy; Humans; Ovarian Hyperstimulation Synd | 1997 |
[Bartter's syndrome: Recurrence in the course of a treatment inhibiting prostaglandin synthesis].
Topics: Adult; Aldosterone; Bartter Syndrome; Depression, Chemical; Female; Humans; Hyperaldosteronism; Indo | 1979 |
Corticosterone methyl oxidase type II deficiency: a cause of failure to thrive and recurrent dehydration in early infancy.
Topics: 18-Hydroxycorticosterone; Aldosterone; Cytochrome P-450 CYP11B2; Dehydration; Diagnosis, Differentia | 1992 |
Recurrent Cushing's disease following "total" adrenalectomy.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adrenal Glands; Adrenalectomy; Adrenocorticotropic Hormo | 1972 |
Recurrent hyperkalaemia due to selective aldosterone deficiency: correction by angiotensin infusion.
Topics: Adrenal Glands; Adrenal Insufficiency; Aged; Aldosterone; Angiotensin II; Autopsy; Diet Therapy; Fem | 1973 |
Control of sodium homeostasis in children with recurrent urinary tract infections and reduced glomerular filtration rates.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adolescent; Aldosterone; Blood Pressure; Child; Diuresis | 1971 |